Allison W. Kurian
YOU?
Author Swipe
View article: Susan G. Komen’s ShareForCures®: a patient-engaged, nationwide breast cancer research registry
Susan G. Komen’s ShareForCures®: a patient-engaged, nationwide breast cancer research registry Open
ShareForCures® is a newly launched and growing dataset, crowd-sourced from participants, that comprises self-reported, clinical, and genomics data. ShareForCures seeks to advance breast cancer research by expanding patient participation in…
View article: Stem Cell Secretome Treatment Reduces Adiposity and Improves Glucose Handling During Obesity and Weight Loss in Mice
Stem Cell Secretome Treatment Reduces Adiposity and Improves Glucose Handling During Obesity and Weight Loss in Mice Open
Objective In this study, we investigated the effects of a stem cell‐derived secretome product on adiposity and tissue quality and insulin and glucose levels in obese mice and those undergoing dietary weight loss. Methods Following 16 weeks…
View article: Figure S3 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
Figure S3 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression Open
Figure S3
View article: Figure S6 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
Figure S6 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression Open
Figure S6
View article: Data from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
Data from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression Open
V-domain immunoglobulin suppressor of T-cell activation (VISTA, VSIR) is a key immune checkpoint receptor under investigation as a target for cancer immunotherapy. However, a better understanding of the signaling mechanisms of VISTA is nee…
View article: Figure S4 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
Figure S4 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression Open
Figure S4
View article: Figure S5 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
Figure S5 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression Open
Figure S5
View article: Figure S2 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
Figure S2 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression Open
Figure S2
View article: Figure S1 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
Figure S1 from A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression Open
Figure S1
View article: Macrophage metabolic rewiring rejuvenates muscle Raman signatures and cellular remodeling during regrowth in aged mice
Macrophage metabolic rewiring rejuvenates muscle Raman signatures and cellular remodeling during regrowth in aged mice Open
Impaired muscle regrowth in aging is underpinned by reduced proinflammatory macrophage function and subsequently impaired muscle cellular remodeling. Macrophage phenotype is metabolically controlled through TCA intermediate accumulation an…
View article: ClinVar Database Evolution and Impact on Potential Pathogenic Germline Variant Reporting from Tumor Comprehensive Genomic Profiling
ClinVar Database Evolution and Impact on Potential Pathogenic Germline Variant Reporting from Tumor Comprehensive Genomic Profiling Open
Although recommended for a high percentage of patients with cancer, germline genetic testing is widely underutilized. Classification of pathogenic variants of potential germline origin (potential pathogenic germline variants; PPGV) from tu…
View article: A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression Open
V-domain immunoglobulin suppressor of T-cell activation (VISTA, VSIR) is a key immune checkpoint receptor under investigation as a target for cancer immunotherapy. However, a better understanding of the signaling mechanisms of VISTA is nee…
View article: Automatic Abstraction of Computed Tomography Imaging Indication Using Natural Language Processing for Evaluation of Surveillance Patterns in Long-Term Lung Cancer Survivors
Automatic Abstraction of Computed Tomography Imaging Indication Using Natural Language Processing for Evaluation of Surveillance Patterns in Long-Term Lung Cancer Survivors Open
PURPOSE Despite its routine use to monitor patients with lung cancer (LC), real-world evaluations of the impact of computed tomography (CT) surveillance on overall survival (OS) have been inconsistent. A major confounder is the absence of …
View article: Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling
Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling Open
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has disrupted breast cancer control through short-term declines in screening and delays in diagnosis and treatments. We projected the impact of COVID-19 on future breast cancer m…
View article: Table 4 from Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, <i>ATM</i>, <i>CHEK2</i>, and <i>PALB2</i>
Table 4 from Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, <i>ATM</i>, <i>CHEK2</i>, and <i>PALB2</i> Open
Exploratory analysis using multivariable models of the increase in the odds of developing breast cancer in carriers of PVs in genes grouped by ER status of associated cancers by risk factor
View article: Supplementary Methods from Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, <i>ATM</i>, <i>CHEK2</i>, and <i>PALB2</i>
Supplementary Methods from Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, <i>ATM</i>, <i>CHEK2</i>, and <i>PALB2</i> Open
Supplementary methods
View article: Table 1 from Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, <i>ATM</i>, <i>CHEK2</i>, and <i>PALB2</i>
Table 1 from Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, <i>ATM</i>, <i>CHEK2</i>, and <i>PALB2</i> Open
Participant characteristics of WHI ASs AS508 and AS551
View article: Table 2 from Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, <i>ATM</i>, <i>CHEK2</i>, and <i>PALB2</i>
Table 2 from Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, <i>ATM</i>, <i>CHEK2</i>, and <i>PALB2</i> Open
Prevalence and penetrance of BRCA1, BRCA2, ATM, CHEK2, and PALB2 PVs
View article: Table 3 from Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, <i>ATM</i>, <i>CHEK2</i>, and <i>PALB2</i>
Table 3 from Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, <i>ATM</i>, <i>CHEK2</i>, and <i>PALB2</i> Open
Multivariable models of the odds of developing breast cancer in carriers of PVs by risk factor
View article: Data from Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, <i>ATM</i>, <i>CHEK2</i>, and <i>PALB2</i>
Data from Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, <i>ATM</i>, <i>CHEK2</i>, and <i>PALB2</i> Open
There are limited prospective data on whether established risk factors modify breast cancer risk in women with pathogenic variants (PV) in BRCA1/2 and virtually no risk modification data for ATM, CHEK2, or PALB2. We conducted a nested case…
View article: Supplementary Table 1 from Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, <i>ATM</i>, <i>CHEK2</i>, and <i>PALB2</i>
Supplementary Table 1 from Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, <i>ATM</i>, <i>CHEK2</i>, and <i>PALB2</i> Open
Supplementary Table 1
View article: A Platform for Mitochondrial Profiling in Enriched Kidney Segments Under Thermodynamic Control in Mice and Humans
A Platform for Mitochondrial Profiling in Enriched Kidney Segments Under Thermodynamic Control in Mice and Humans Open
Mitochondrial function varies widely across kidney nephron segments, yet conventional approaches lack the resolution and control needed to assess cell-type-specific bioenergetics in situ. We present a methodological platform that enables s…
View article: Association of Polygenic-Based Breast Cancer Risk Prediction With Patient Management
Association of Polygenic-Based Breast Cancer Risk Prediction With Patient Management Open
PURPOSE Breast cancer (BC) risk prediction is more accurate when clinical and polygenic factors are combined (combined risk score [CRS]), but little is known about how CRS results affect real-world patient management. METHODS Deidentified …
View article: Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i> , <i>BRCA2</i> , <i>ATM</i> , <i>CHEK2</i> , and <i>PALB2</i>
Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i> , <i>BRCA2</i> , <i>ATM</i> , <i>CHEK2</i> , and <i>PALB2</i> Open
There are limited prospective data on whether established risk factors modify breast cancer risk in women with pathogenic variants (PV) in BRCA1/2 and virtually no risk modification data for ATM, CHEK2, or PALB2. We conducted a nested case…
View article: Patient-Centered Research Through Artificial Intelligence to Identify Priorities in Cancer Care
Patient-Centered Research Through Artificial Intelligence to Identify Priorities in Cancer Care Open
Importance Patient-centered research is essential for bridging the gap between research and patient care, yet patient perspectives are often inadequately represented in health research. Objective To leverage artificial intelligence (AI) an…
View article: Extended endocrine therapy use and decision making after breast cancer diagnosis
Extended endocrine therapy use and decision making after breast cancer diagnosis Open
Background Adjuvant endocrine therapy is recommended to extend beyond 5 years for stage II breast cancer, with less consensus for extension in stage I. We aimed to understand use of and decision making about extended endocrine therapy. Met…